BASF expands peptide portfolio with Pepsensyal
General

BASF expands peptide portfolio with Pepsensyal

Clinically proven to re-densify and resurface skin and smooth theappearance of crow's feet

  • By ICN Bureau | October 23, 2024

BASF’s Personal Care business is launching a new synthetic peptide for skin care applications. Inspired by the natural regenerative process of the skin, Pepsensyal (INCI: Mannitol (and) Acetyl sh-Tetrapeptide-1 (and) Lauroyl sh-Tetrapeptide-1) has been clinically proven to reduce and delay the first visible signs of aging.

The new ingredient is a response to the slow-aging trend, which reflects a shift in consumer attitudes: Rather than fighting the natural aging process, consumers are increasingly concerned with healthy aging through a holistic, preventative approach to skin care.

In recent years, peptides in particular have gained a lot of traction in the personal care market and are recognized by consumers as effective, science-backed ingredients. Pepsensyal expands BASF's peptide portfolio with a new cost-effective variant. The new ingredient is free of preservatives and 99% of natural origin.

In a double-blind, randomized, split-face clinical trial with 32 women aged between 44 and 64, Pepsensyal at 0.2% was tested against a placebo product without the new ingredient. After only 14 days, crow's feet appeared smoother, with an 11% decrease in average roughness and a 14% decrease in maximum relief amplitude.

At the same time, skin isotropy increased by 15%, indicating a skin resurfacing effect. In that same test, Pepsensyal was also proven to replenish the skin from the inside: After 28 days, the skin had re-densified, with a 21% increase in the echogenic surface area of the dermis.

Extensive in vitro testing has confirmed the ingredient's ability to support skin regeneration, helping to slow the visible signs of skin aging.

Other Related stories

Startups

Chemical

Petrochemical

Energy

Digitization